• Thomas K. Equels, CEO, President, director, bought 24,000 AIM ImmunoTech common shares at $0.21 each.
• Direct holdings rose to 126,822 shares following the purchase.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-043246), on September 18, 2026, and is solely responsible for the information contained therein.